Cargando…
Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study
OBJECTIVES: Large population-based studies on the incidence and outcome of non-small cell lung cancer (NSCLC) are lacking in mainland China. This study aimed to investigate the NSCLC incidence, demographic features and survival as well as factors affecting survival of patients with NSCLC in Shanghai...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691760/ https://www.ncbi.nlm.nih.gov/pubmed/26700282 http://dx.doi.org/10.1136/bmjopen-2015-009419 |
_version_ | 1782407190807576576 |
---|---|
author | Fan, Heng Shao, Zhen-Yi Xiao, Yuan-Yuan Xie, Zhi-Hui Chen, Wen Xie, Hua Qin, Guo-You Zhao, Nai-Qing |
author_facet | Fan, Heng Shao, Zhen-Yi Xiao, Yuan-Yuan Xie, Zhi-Hui Chen, Wen Xie, Hua Qin, Guo-You Zhao, Nai-Qing |
author_sort | Fan, Heng |
collection | PubMed |
description | OBJECTIVES: Large population-based studies on the incidence and outcome of non-small cell lung cancer (NSCLC) are lacking in mainland China. This study aimed to investigate the NSCLC incidence, demographic features and survival as well as factors affecting survival of patients with NSCLC in Shanghai. DESIGN: Prospective observational cohort study. SETTING: Baseline information was collected from Shanghai Health Information Network, which is based on the Health Information Systems from all the comprehensive hospitals and specialist hospitals qualified for cancer diagnosis in the Shanghai metropolitan area. PARTICIPANTS: All NSCLC cases identified from the database between 2011 and 2013 were recruited (15 020 patients). MAIN RESULTS: The crude and age-adjusted incidences of NSCLC were 54.20 per 100 000 people (55.90 per 100 000 for men, 52.39 per 100 000 for women) and 39.05 per 100 000 people (41.43 per 100 000 for men and 37.13 per 100 000 for women), respectively. The median survival time was 22.7 months (95% CI 21.8 to 24.2 months) with an overall 1-year survival rate of 71.8% (95% CI 69.8% to 73.8%). The 1-year survival rate was 96.5% (95% CI 94.0% to 98.6%) in patients with stage I NSCLC, 89.1% (95% CI 83.3% to 94.9%) in patients with stage II NSCLC, 78.8% (95% CI 74.1% to 83.5%) in patients with stage IIIa NSCLC and 58.9% (95% CI 56.1% to 61.7%) in patients with stage IIIb/IV NSCLC. Multivariate analysis showed surgical resection (HR=0.607, 95% CI 0.511 to 0.722) and chemotherapy (HR=0.838, 95% CI 0.709 to 0.991) significantly improved survival. Factors associated with poor survival included older age, male sex, larger tumour size, lymph node metastasis, distant metastasis and squamous cell carcinoma. CONCLUSIONS: A higher incidence and better survival rates for patients with NSCLC were identified when compared with previously published studies, which may provide evidence on the incidence and survival of NSCLC in China. |
format | Online Article Text |
id | pubmed-4691760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46917602015-12-30 Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study Fan, Heng Shao, Zhen-Yi Xiao, Yuan-Yuan Xie, Zhi-Hui Chen, Wen Xie, Hua Qin, Guo-You Zhao, Nai-Qing BMJ Open Oncology OBJECTIVES: Large population-based studies on the incidence and outcome of non-small cell lung cancer (NSCLC) are lacking in mainland China. This study aimed to investigate the NSCLC incidence, demographic features and survival as well as factors affecting survival of patients with NSCLC in Shanghai. DESIGN: Prospective observational cohort study. SETTING: Baseline information was collected from Shanghai Health Information Network, which is based on the Health Information Systems from all the comprehensive hospitals and specialist hospitals qualified for cancer diagnosis in the Shanghai metropolitan area. PARTICIPANTS: All NSCLC cases identified from the database between 2011 and 2013 were recruited (15 020 patients). MAIN RESULTS: The crude and age-adjusted incidences of NSCLC were 54.20 per 100 000 people (55.90 per 100 000 for men, 52.39 per 100 000 for women) and 39.05 per 100 000 people (41.43 per 100 000 for men and 37.13 per 100 000 for women), respectively. The median survival time was 22.7 months (95% CI 21.8 to 24.2 months) with an overall 1-year survival rate of 71.8% (95% CI 69.8% to 73.8%). The 1-year survival rate was 96.5% (95% CI 94.0% to 98.6%) in patients with stage I NSCLC, 89.1% (95% CI 83.3% to 94.9%) in patients with stage II NSCLC, 78.8% (95% CI 74.1% to 83.5%) in patients with stage IIIa NSCLC and 58.9% (95% CI 56.1% to 61.7%) in patients with stage IIIb/IV NSCLC. Multivariate analysis showed surgical resection (HR=0.607, 95% CI 0.511 to 0.722) and chemotherapy (HR=0.838, 95% CI 0.709 to 0.991) significantly improved survival. Factors associated with poor survival included older age, male sex, larger tumour size, lymph node metastasis, distant metastasis and squamous cell carcinoma. CONCLUSIONS: A higher incidence and better survival rates for patients with NSCLC were identified when compared with previously published studies, which may provide evidence on the incidence and survival of NSCLC in China. BMJ Publishing Group 2015-12-23 /pmc/articles/PMC4691760/ /pubmed/26700282 http://dx.doi.org/10.1136/bmjopen-2015-009419 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Oncology Fan, Heng Shao, Zhen-Yi Xiao, Yuan-Yuan Xie, Zhi-Hui Chen, Wen Xie, Hua Qin, Guo-You Zhao, Nai-Qing Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study |
title | Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study |
title_full | Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study |
title_fullStr | Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study |
title_full_unstemmed | Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study |
title_short | Incidence and survival of non-small cell lung cancer in Shanghai: a population-based cohort study |
title_sort | incidence and survival of non-small cell lung cancer in shanghai: a population-based cohort study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691760/ https://www.ncbi.nlm.nih.gov/pubmed/26700282 http://dx.doi.org/10.1136/bmjopen-2015-009419 |
work_keys_str_mv | AT fanheng incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT shaozhenyi incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT xiaoyuanyuan incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT xiezhihui incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT chenwen incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT xiehua incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT qinguoyou incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy AT zhaonaiqing incidenceandsurvivalofnonsmallcelllungcancerinshanghaiapopulationbasedcohortstudy |